Breast Tumors Shed Their HER2 Target in More Than Half of Cases After Drug Therapy
A new MD Anderson study finds that 57 percent of residual breast tumors lose HER2 overexpression after HER2-targeted neoadjuvant therapy, ...
A new MD Anderson study finds that 57 percent of residual breast tumors lose HER2 overexpression after HER2-targeted neoadjuvant therapy, ...
A new review in Molecular Cancer argues that extrachromosomal DNA acts as a dynamic epigenetic reprogramming platform that reshapes chromatin, ...
A machine learning radiomics approach that maps internal tumor habitats on venous-phase CT scans accurately distinguishes retroperitoneal dedifferentiated liposarcoma from ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine